首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Preclinical evaluation of thermoreversible triamcinolone acetonide hydrogels for drug delivery to the inner ear
【2h】

Preclinical evaluation of thermoreversible triamcinolone acetonide hydrogels for drug delivery to the inner ear

机译:热可逆曲安奈德丙酮水凝胶用于药物输送到内耳的临床前评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="kwd-title">Abbreviations: POX 407, Poloxamer 407; TAAc, Triamcinolone acetonide; DEX, Dexamethasone; POX 188, Poloxamer 188; ORO-test, Oscillation–rotation–oscillation test class="kwd-title">Keywords: Triamcinolone acetonide, Thermoreversible hydrogel, Poloxamer 407, Intratympanic administration, In-vitro release class="head no_bottom_margin" id="idm139856046189184title">AbstractIntratympanic glucocorticoid therapy aims to reduce the side effects associated with systemic long-time therapy of inner ear diseases or traumata after cochlear implantation. For that purpose, thermoreversible hydrogels being fluid at room temperature but solid at body temperature are known to be appropriate drug delivery systems. In this work, the two key parameters sol–gel transition time and temperature of Poloxamer 407 (POX 407) based hydrogels containing oto-compatible micronized triamcinolone acetonide (TAAc) were evaluated by rheological experiments varying the concentrations of the different compounds. A 20% POX 407 hydrogel in PBS containing 30% TAAc emerged as the most appropriate formulation. Oscillation–rotation–oscillation studies at two temperature levels were found to be an useful in-vitro test system for the hydrogel which revealed sufficient storage stability at 4 °C, injectability of the sol, solidification within 20 s at body temperature and persistent stiffness indicating prolonged adhesion at the round window membrane. According to the in-vitro release studies using the Transwell™ system, absorption of the poor water soluble TAAc is partly due to the low amount of dissolved drug but predominantly due to micellar transport resulting in a cumulative release of 262.6 ± 13.4 μg TAAc within one week followed by a sustained release of 193.1 ± 8.3 μg TAAc within the next three weeks. Thus, the formation of POX 407 micelles is the basis not only for gel formation but also absorptivity of TAAc. All in all, fine tuned rheological experiments and absorption studies emerged as useful tools for preclinical evaluation of intratympanally administered hydrogels.
机译:<!-fig ft0-> <!-fig @ position =“ anchor” mode =文章f4-> <!-fig mode =“ anchred” f5-> <!-fig / graphic | fig / alternatives / graphic mode =“ anchored” m1-> class =“ kwd-title”>缩写: POX 407,泊洛沙姆407; TAAc,曲安奈德; DEX,地塞米松; POX 188,泊洛沙姆188; ORO测试,振荡-旋转-振荡测试 class =“ kwd-title”>关键字:醋酸曲安奈德,热可逆水凝胶,泊洛沙姆407,鼓室内给药,体外释放 class =“ head no_bottom_margin” id =“ idm139856046189184title”>摘要鼓室内糖皮质激素治疗旨在减少与人工耳蜗植入后内耳疾病或创伤的全身长期治疗相关的副作用。为此,已知在室温下为流体但在体温下为固体的热可逆水凝胶是合适的药物递送系统。在这项工作中,通过流变学实验改变了不同化合物的浓度,评估了含oto相容性微粉化曲安奈德丙酮(TAAc)的基于Poloxamer 407(POX 407)的水凝胶的两个关键参数,溶胶-凝胶转变时间和温度。 PBS中含有30%TAAc的20%POX 407水凝胶是最合适的配方。发现在两个温度水平下的振荡-旋转-振荡研究是一种有用的水凝胶体外测试系统,该系统显示出在4°C时具有足够的储存稳定性,溶胶的可注射性,在体温下20秒钟内固化以及持久的刚度表明在圆窗膜上的附着力延长。根据使用Transwell™系统进行的体外释放研究,吸收不良的水溶性TAAc的部分原因是溶解的药物量少,但主要是由于胶束运输导致一个内累积释放262.6±13.4μgTAAc一周后在接下来的三周内持续释放193.1±8.3μgTAAc。因此,POX 407胶束的形成不仅是凝胶形成的基础,而且是TAAc的吸收性的基础。总而言之,微调的流变实验和吸收研究已成为临床上评估鼓膜内给药水凝胶的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号